about
Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Noise-induced nitrotyrosine increase and outer hair cell death in guinea pig cochleaChemical model systems for cellular nitros(yl)ation reactions.ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease.Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system.Systematic analysis of the ability of Nitric Oxide donors to dislodge biofilms formed by Salmonella enterica and Escherichia coli O157:H7.Effects of Aging and Oxidative Stress on Spermatozoa of Superoxide-Dismutase 1- and Catalase-Null Mice.Aged neuronal nitric oxide knockout mice show preserved olfactory learning in both social recognition and odor-conditioning tasksInfluence of nitrovasodilators and endothelin-1 on rheology of human blood in vitro.Tyrosine nitration in prostaglandin H(2) synthase.Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats.Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells.Comparative short-term effect of once-daily molsidomine on chronic angina in general practitioners' versus cardiologists' coronary patient populations.
P2860
Q26742059-C14658B9-D1EC-4F07-A395-3CCC538A73C0Q30441952-8DD0FE6C-F0A9-436C-A35F-C12B84AE2B30Q33552757-41DEEBA5-0A6B-4FF8-AD02-03703B3A3D10Q34762292-F396B1E9-34FC-4F63-B90C-8A9596C1F64CQ38076347-8E12425D-0047-4DB1-B4B2-4F7D06D05F6EQ38204833-64A806E3-5C4C-4412-B619-A2EF9F964F44Q38706678-0C95AA2D-C07E-406D-9B14-758BD1737A7BQ41141047-65C9E1E7-D429-4FF0-A4DA-3F1B761FDC33Q41808169-4AEAF68D-1E45-4E50-AF4A-DD33FBEA4809Q42076730-54899D0B-D6D5-4D75-A830-748397AB3806Q43260499-DE2AEB17-788D-4B0C-A984-C78E4EDA504BQ44168316-90BE24A5-793F-4031-BBDA-BDAEBC20C854Q44633014-3DB72B4B-9638-4276-9267-806EDCDB1918Q44746404-0656C798-D901-4686-BF42-4ADD9BBD0B9FQ54488507-E84A1707-E374-4003-8CC9-0FC76B6568F8
P2860
description
1996 nî lūn-bûn
@nan
1996 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Clinical pharmacokinetics of molsidomine.
@ast
Clinical pharmacokinetics of molsidomine.
@en
Clinical pharmacokinetics of molsidomine.
@nl
type
label
Clinical pharmacokinetics of molsidomine.
@ast
Clinical pharmacokinetics of molsidomine.
@en
Clinical pharmacokinetics of molsidomine.
@nl
prefLabel
Clinical pharmacokinetics of molsidomine.
@ast
Clinical pharmacokinetics of molsidomine.
@en
Clinical pharmacokinetics of molsidomine.
@nl
P2093
P1476
Clinical pharmacokinetics of molsidomine.
@en
P2093
Parnham MJ
Rosenkranz B
Winkelmann BR
P304
P356
10.2165/00003088-199630050-00004
P577
1996-05-01T00:00:00Z
P6179
1009799607